|
|
Post by mssciguy on Nov 18, 2015 9:31:58 GMT -5
|
|
|
|
Post by bradleysbest on Nov 18, 2015 10:00:11 GMT -5
I do not see Afrezza mentioned on the brochure. Will Afrezza be discussed at this clinic?
|
|
|
|
Post by mssciguy on Nov 18, 2015 10:04:07 GMT -5
I do not see Afrezza mentioned on the brochure. Will Afrezza be discussed at this clinic? Do you know of any other inhaled insulins  Yeah it took me a couple minutes too |
|
|
|
Post by bradleysbest on Nov 18, 2015 10:10:33 GMT -5
True but why not spell out Afrezza! Neither Edeleman or Polonsky are on Afrezzauser's website for doctors prescribing Afrezza....
|
|
|
|
Post by mssciguy on Nov 18, 2015 10:17:38 GMT -5
True but why not spell out Afrezza! Neither Edeleman or Polonsky are on Afrezzauser's website for doctors prescribing Afrezza.... "supported by an educational grant by Sanofi" --- There may be rules about specifying product names. The current lists of prescribers are not complete, how could they be? Sanofi probably knows who's prescribing though (one would hope). |
|
|
|
Post by bradleysbest on Nov 18, 2015 10:24:02 GMT -5
Agree with your points but these limitations (secrecy) are driving me crazy! Hopefully we have someone in San Diego who is a part of this board that can attend & give us some real feed back.
Ps... You have good eyes! I have to blow these pages up to see the fine print! LOL
|
|
|
|
Post by suebeeee1 on Nov 18, 2015 11:15:36 GMT -5
Mssciguy, have you made Afrezza your full time job? I think you are now competing with Harry. How many "bots" do you have working on digging this stuff out on the internet. I wouldn't even know where to begin to find a pamphlet for a seminar on a specific, non searchable website.
|
|
|
|
Post by mssciguy on Nov 18, 2015 11:21:17 GMT -5
Mssciguy, have you made Afrezza your full time job? I think you are now competing with Harry. How many "bots" do you have working on digging this stuff out on the internet. I wouldn't even know where to begin to find a pamphlet for a seminar on a specific, non searchable website. No, I'll get back to the real world within a day or two What I do is graze ymb and stocktwits from time to time, and cull (hopefully) the best to share here. I really wanted to be here until the price starts moving up again. I've invested in companies in years past that were destroyed by hedge funds, just for profit. Don't ever want that to happen again. (OT: check out what happened to SUNE, HFs tried to destroy it, good example of the forces of evil on Wall Street) |
|
|
|
Post by kc on Nov 18, 2015 12:12:14 GMT -5
I do not see Afrezza mentioned on the brochure. Will Afrezza be discussed at this clinic? Dr. Edelman has traveled accross the country speaking about Afrezza. He is on the Afrezza speaking tour. This was a good point on th flyer. 5. Integrate effective strategies for overcoming patients and HCP resistance to titrating
mealtime insulin
Here is a link to a slide deck from a presentation that Dr. Edelman did in Phoenix in September with a Dr. Ian Blumer. You can see how he focuses on Afrezza as the right mealtime Insulin. you have to page down to get to the 2nd presentaton. Slides 1-12, 25 tcoyd.org/PDF/FULLCOLOR_PHOENIX.pdfLecture 2: 7:45 – 8:30 p.m. Ian Blumer, MD, FRCPC Presents: New and Novel Insulins on the Therapeutic Horizon |
|
|
|
Post by kc on Nov 18, 2015 12:40:41 GMT -5
Slide deck from the Dinner in Salt Lake City.
Continuing Medical Education Dinner Program
Salt Lake City, UT CME Dinner Program
Thursday, October 29, 2015
Salt Lake Marriott City Center
220 South State Street
Salt Lake City, UT 84111
Lecture 2: 7:45 – 8:30 p.m.
Slides 1-20
Steven V. Edelman, MD Presents:
A Case-Based Look at Practical Clinical Strategies to Address Postprandial
Hyperglycemia in Type 1 and Type 2 Diabetes
tcoyd.org/PDF/2015-saltlake-postp-slides.pdf
|
|
|
|
Post by compound26 on Nov 18, 2015 15:59:33 GMT -5
I am copying my comments in another post here as it is also related to this thread ( apologize for the repeat).  Sanofi really needs to have docfrezza, or Biran's or Sam's physicians, etc. (i.e., those high volume Afrezza prescribes (see this post)) to be all over the places to talk about the real life A1Cs improvements they have witnessed in their practices to their peers. Like the A1C improvement from 12 to 7 as described by docfrezza (in this post). That will be very persuasive to their peers.
I like what Sanofi is doing in regarding to CLEs like those mentioned here. I like seeing Edeleman or Polonsky doing these type of presentations. However, if Edeleman or Polonsky does not prescribe Afrezza or if they presribe Afrezza, but are not talking about the real life A1Cs improvements they have witnessed in their practices, then Sanofi needs to make sure that these speakers/CLEs are supplemented by talks from the high volume Afrezza prescribes talking about the real life A1Cs improvements they have witnessed in their practices. Afrezza has been launched 9 months, and the high volume Afrezza prescribes already have seen the real life A1Cs improvements and other overall health and quality of life improvements in their patients. Sanofi really needs to make use of such real life information to upgrade their CLE (or other) presentations/discussions, if they have not done so. And it appears Sanofi has not done so yet (or not in any large scale yet) as I understand docfrezza (as one of the few high volume Afrezza prescribes) has yet to be invited by Sanofi to give such talks. Read more: mnkd.proboards.com/post/47461 |
|
|
|
Post by mssciguy on Nov 18, 2015 16:13:50 GMT -5
I am copying my comments in another post here as it is also related to this thread ( apologize for the repeat). Sanofi really needs to have docfrezza, or Biran's or Sam's physicians, etc. (i.e., those high volume Afrezza prescribes (see this post)) to be all over the places to talk about the real life A1Cs improvements they have witnessed in their practices to their peers. Like the A1C improvement from 12 to 7 as described by docfrezza (in this post). That will be very persuasive to their peers.
I like what Sanofi is doing in regarding to CLEs like those mentioned here. I like seeing Edeleman or Polonsky doing these type of presentations. However, if Edeleman or Polonsky does not prescribe Afrezza or if they presribe Afrezza, but are not talking about the real life A1Cs improvements they have witnessed in their practices, then Sanofi needs to make sure that these speakers/CLEs are supplemented by talks from the high volume Afrezza prescribes talking about the real life A1Cs improvements they have witnessed in their practices. Afrezza has been launched 9 months, and the high volume Afrezza prescribes already have seen the real life A1Cs improvements and other overall health and quality of life improvements in their patients. Sanofi really needs to make use of such real life information to upgrade their CLE (or other) presentations/discussions, if they have not done so. And it appears Sanofi has not done so yet (or not in any large scale yet) as I understand docfrezza (as one of the few high volume Afrezza prescribes) has yet to be invited by Sanofi to give such talks. Read more: mnkd.proboards.com/post/47461Another board member contacted Edelman and asked whether Edelman prescribed Afrezza, answer was, "of course" (I don't want to reveal identity without permission but he can chime in if he likes) |
|
|
|
Post by compound26 on Nov 18, 2015 16:26:49 GMT -5
I am copying my comments in another post here as it is also related to this thread ( apologize for the repeat). Sanofi really needs to have docfrezza, or Biran's or Sam's physicians, etc. (i.e., those high volume Afrezza prescribes (see this post)) to be all over the places to talk about the real life A1Cs improvements they have witnessed in their practices to their peers. Like the A1C improvement from 12 to 7 as described by docfrezza (in this post). That will be very persuasive to their peers.
I like what Sanofi is doing in regarding to CLEs like those mentioned here. I like seeing Edeleman or Polonsky doing these type of presentations. However, if Edeleman or Polonsky does not prescribe Afrezza or if they presribe Afrezza, but are not talking about the real life A1Cs improvements they have witnessed in their practices, then Sanofi needs to make sure that these speakers/CLEs are supplemented by talks from the high volume Afrezza prescribes talking about the real life A1Cs improvements they have witnessed in their practices. Afrezza has been launched 9 months, and the high volume Afrezza prescribes already have seen the real life A1Cs improvements and other overall health and quality of life improvements in their patients. Sanofi really needs to make use of such real life information to upgrade their CLE (or other) presentations/discussions, if they have not done so. And it appears Sanofi has not done so yet (or not in any large scale yet) as I understand docfrezza (as one of the few high volume Afrezza prescribes) has yet to be invited by Sanofi to give such talks. Read more: mnkd.proboards.com/post/47461Another board member contacted Edelman and asked whether Edelman prescribed Afrezza, answer was, "of course" (I don't want to reveal identity without permission but he can chime in if he likes) That's great. Hope then in his presentations he can at least drop in some real world information on the life-changing experience of the patients that he witnessed in his practice. |
|
|
|
Post by bradleysbest on Nov 18, 2015 16:47:47 GMT -5
I did email Edelman & he confirmed he does prescribe Afrezza. He has hosted many of these dinner seminars touting the benefits of Afrezza. You can find a listing of the seminars on tcoyd.org. Polonsky is on the behavioral side & does not prescribe Afrezza.
|
|
|
|
Post by kc on Nov 19, 2015 7:44:32 GMT -5
I think the real point is missed by all of us. We are just too impatient and want to see this take off tomorrow. But the reality is that most Endos and doctors are very conservative people. You don't get them to prescribe new medicines very fast until it's proven they are beneficial to their patients. Until the time when this product is more acceptable it will be a slow go like we have seen so far. I don't think were at risk for termination by I don't think were at risk for termination by sanofi as a know how the game is played.
|
|
Yeah it took me a couple minutes too
